Quantitating therapeutically relevant T-cell responses to cancer vaccines.
Crit Rev Immunol
; 21(1-3): 287-97, 2001.
Article
de En
| MEDLINE
| ID: mdl-11642610
ABSTRACT
Successful application of active immunotherapy to the treatment of cancer will require stimulation of potent antigen-specific T-cell responses. It is not known how numerous or how potent these T cells must be in order to abrogate tumors, but the levels of immunity needed to control chronic viral infections may provide estimates for comparison. Evaluation of the efficacy of a vaccine strategy in attaining these levels of immunity will depend on the use of assays that create a picture of T-cell number and function that correlates with clinical outcomes. We discuss the currently available in vivo and in vitro T-cell assays and their relevance for detecting therapeutic levels of T-cell activity. We also propose a strategy for efficiently evaluating the immunologic efficacy of cancer vaccines so that the most promising candidates can be brought more rapidly into definitive clinical trials.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Lymphocytes T
/
Vaccins anticancéreux
Limites:
Humans
Langue:
En
Journal:
Crit Rev Immunol
Sujet du journal:
ALERGIA E IMUNOLOGIA
Année:
2001
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique